Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

Principal Investigator: Wang, Eunice S

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

Principal Investigator: Cortese, Matthew J

MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication Adherence

Principal Investigator: Kelly, Kara M

Asciminib as Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia who do not Achieve Optimal Response or a Deep Molecular Remission (ALERT CML)

Principal Investigator: Thompson, J

A Phase II Study of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia

Principal Investigator: Green, Steven D

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1…

Principal Investigator: Wang, Eunice S

2215-CL-0203 A Phase 1/2, Multicenter, Open-Label, Randomized, Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for…

Principal Investigator: Wang, Eunice S

Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia

Principal Investigator: Wang, Eunice S

A FIRST-IN-HUMAN, PHASE 1, DOSE ESCALATION STUDY OF SGR-2921 AS MONOTHERAPY IN SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME

Principal Investigator: Wang, Eunice S

KOMEN-008: A Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

(AALL2121) A Phase 2 study of revumenib (SNDX-5613) in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia

Principal Investigator: Mallhi, Kanwal

A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)…

Principal Investigator: Wang, Eunice S

A single-arm, open-label, Dose Escalation + Cohort Expansion Phase 1 Trial to Determine the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 given orally to Patients with Refractory or Relapsed Chronic Myelogenous Leukemia

Principal Investigator: Thompson, J

(AALL1621) A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Principal Investigator: Twist, Clare J

(AALL1732) A Phase 3 Randomized Trial of Inotuzumab Ozogamicin(IND#:133494, NSC#:772518)for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-InductionTherapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Principal Investigator: Twist, Clare J

A bilingual virtually-based intervention (PEDALL) for the prevention of weight gain in childhood ALL patients considering key genetic and sociodemographic risk factors

Principal Investigator: Kelly, Kara M

A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Principal Investigator: Wang, Eunice S

(ASCT2031) A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or…

Principal Investigator: Twist, Clare J

A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT)

Principal Investigator: Mallhi, Kanwal

A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next…

Principal Investigator: Mallhi, Kanwal